JP2019521180A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521180A5
JP2019521180A5 JP2019516091A JP2019516091A JP2019521180A5 JP 2019521180 A5 JP2019521180 A5 JP 2019521180A5 JP 2019516091 A JP2019516091 A JP 2019516091A JP 2019516091 A JP2019516091 A JP 2019516091A JP 2019521180 A5 JP2019521180 A5 JP 2019521180A5
Authority
JP
Japan
Prior art keywords
composition
chemotherapeutic
administration
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521180A (ja
JP7025416B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035991 external-priority patent/WO2017214052A1/en
Publication of JP2019521180A publication Critical patent/JP2019521180A/ja
Publication of JP2019521180A5 publication Critical patent/JP2019521180A5/ja
Priority to JP2022019473A priority Critical patent/JP7405881B2/ja
Application granted granted Critical
Publication of JP7025416B2 publication Critical patent/JP7025416B2/ja
Priority to JP2023211483A priority patent/JP2024028993A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516091A 2016-06-06 2017-06-05 好中球減少症を低減させるための組成物および方法 Active JP7025416B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022019473A JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346426P 2016-06-06 2016-06-06
US62/346,426 2016-06-06
US201762454628P 2017-02-03 2017-02-03
US62/454,628 2017-02-03
PCT/US2017/035991 WO2017214052A1 (en) 2016-06-06 2017-06-05 Composition and method for reducing neutropenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022019473A Division JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019521180A JP2019521180A (ja) 2019-07-25
JP2019521180A5 true JP2019521180A5 (enExample) 2020-07-16
JP7025416B2 JP7025416B2 (ja) 2022-02-24

Family

ID=60578094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019516091A Active JP7025416B2 (ja) 2016-06-06 2017-06-05 好中球減少症を低減させるための組成物および方法
JP2022019473A Active JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A Withdrawn JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022019473A Active JP7405881B2 (ja) 2016-06-06 2022-02-10 好中球減少症を低減させるための組成物および方法
JP2023211483A Withdrawn JP2024028993A (ja) 2016-06-06 2023-12-14 好中球減少症を低減させるための組成物および方法

Country Status (14)

Country Link
US (2) US11229642B2 (enExample)
EP (1) EP3463337A4 (enExample)
JP (3) JP7025416B2 (enExample)
KR (3) KR20240091084A (enExample)
CN (2) CN109475524A (enExample)
AU (1) AU2017278245B2 (enExample)
BR (1) BR112018074990A2 (enExample)
CL (1) CL2018003489A1 (enExample)
IL (1) IL263439B2 (enExample)
MX (1) MX389200B (enExample)
RU (1) RU2760348C2 (enExample)
SG (1) SG11201810872UA (enExample)
TW (1) TWI777957B (enExample)
WO (1) WO2017214052A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736045C2 (ru) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Способ лечения рака, ассоциированного с мутацией ras
US10076518B2 (en) 2015-03-06 2018-09-18 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
US11229642B2 (en) * 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN112105363A (zh) * 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN115531385A (zh) * 2021-06-29 2022-12-30 深圳华泓海洋生物医药有限公司 氘代普那布林在制备治疗中性粒细胞减少症药物中的应用
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850000073B1 (ko) 1979-06-29 1985-02-18 더 웰컴 파운데이숀 리미티드 5-(2-포르밀-3-히드록시페녹시)펜타노익 산류의 제조방법
IL64573A (en) 1980-12-18 1985-04-30 Wellcome Found Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DK0609606T3 (enExample) 1992-10-01 1997-03-17 Wellcome Found
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
DK0674510T3 (da) 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
MXPA00004919A (es) 1997-11-21 2002-10-17 Euro Celtique Sa 2-aminoacetamidas sustituidas y uso de las mismas.
BR9908207A (pt) 1998-01-29 2000-11-28 Aventis Pharm Prod Inc Processo para preparar um composto de n- [ ( (alifático ou aromático) carbonil] -2-aminoacetamida, e, isonitrila ligada à resina
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
WO1999050245A1 (en) 1998-03-26 1999-10-07 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
AU782917C (en) 2000-01-18 2006-11-23 Beyondspring Pharmaceuticals, Inc. Cell division inhibitors and process for producing the same
US6649172B2 (en) 2000-03-17 2003-11-18 Corixa Corporation Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
HUP0302358A3 (en) 2000-05-09 2007-09-28 Adpharma Piperazinedione compounds and use of them for producing pharmaceutical compositions
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ, インコーポレイテッド 三環式crfレセプターアンタゴニスト
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
AU2003244646B2 (en) 2002-05-17 2008-08-07 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7064201B2 (en) 2002-08-02 2006-06-20 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005077940A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ES2527412T3 (es) 2007-02-15 2015-01-23 Mannkind Corporation Método para aumentar la respuesta de los linfocitos T
JP5641927B2 (ja) 2007-04-13 2014-12-17 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Sparc及びその使用方法
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
SG185954A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ctla4 항체의 조합물
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
EP2387420A2 (en) 2009-01-16 2011-11-23 Teva Pharmaceutical Industries Limited New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010101627A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
PL2464218T3 (pl) 2009-08-10 2015-12-31 Univ Texas Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
MX2012004721A (es) 2009-10-23 2012-06-25 Mannkind Corp Inmunoterapia de cancer y metodo de tratamiento.
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
EP2542699A4 (en) 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
CN104024851A (zh) 2011-11-28 2014-09-03 加拿大国家研究委员会 针对癌症的紫杉醇反应标志物
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
DK2846809T3 (da) 2012-05-09 2021-01-18 Cantex Pharmaceuticals Inc Behandling af myelosuppression
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
PT3381942T (pt) 2012-08-30 2021-05-24 Amgen Inc Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário
WO2014051543A1 (en) * 2012-09-25 2014-04-03 Hewlett-Packard Development Company, L.P. Print head die
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
MX374929B (es) 2013-02-20 2025-03-06 Novartis Ag RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
AU2014262469B2 (en) 2013-05-10 2019-11-14 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
JP6311097B2 (ja) 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
US10596169B2 (en) * 2013-10-11 2020-03-24 Beyondspring Inc. Cancer treatment with combination of plinabulin and taxane
EP4461372A3 (en) 2013-11-05 2025-01-22 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3594359B1 (en) 2013-11-06 2022-05-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
CN104796448B (zh) * 2014-01-22 2019-02-12 腾讯科技(深圳)有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
CA2975729A1 (en) 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
RU2736045C2 (ru) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Способ лечения рака, ассоциированного с мутацией ras
US10076518B2 (en) 2015-03-06 2018-09-18 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
CA2991059C (en) 2015-07-13 2024-01-16 Beyondspring Pharmaceuticals, Inc. Plinabulin monohydrate polymorphs
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
US11229642B2 (en) * 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP6779517B2 (ja) 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
JP7280192B2 (ja) 2017-03-13 2023-05-23 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド プリナブリン組成物及びその使用
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN112105363A (zh) 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
JP7500438B2 (ja) 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド Egfr変異に関連する癌の治療組成物及び治療方法
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
CA3119768A1 (en) 2018-11-14 2020-05-22 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
CN113613654B (zh) 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
EP4146216A4 (en) 2020-05-04 2024-05-29 Beyondspring Pharmaceuticals Inc. TRITHERAPY TO IMPROVE THE DESTRUCTION OF CANCER CELLS IN LOW IMMUNOGENICITY CANCERS
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN115703763A (zh) 2021-08-13 2023-02-17 大连万春布林医药有限公司 普那布林或其制剂中的杂质及其用途
CA3234699A1 (en) 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors

Similar Documents

Publication Publication Date Title
JP2019521180A5 (enExample)
RU2018142394A (ru) Композиции и способы для лечения нейтропении
JP2016513657A5 (enExample)
JP2013503174A5 (enExample)
JP2012506448A5 (enExample)
WO2009120697A4 (en) Method and compositions for treatment of cancer
JP2010514787A5 (enExample)
JP2017226708A5 (enExample)
JP2011079858A5 (enExample)
JP2012158602A5 (enExample)
RU2008141763A (ru) Лечение рака молочной железы, негативного по трем рецепторам
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2011515481A5 (enExample)
JP2017533223A5 (enExample)
RU2010140890A (ru) Улучшенные способы противоопухолевого лечения
JP2015514756A5 (enExample)
JP2019533651A5 (enExample)
JP2019509253A5 (enExample)
JP2015518053A5 (enExample)
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
JP2018536655A5 (enExample)
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
JP2018522053A5 (enExample)
JP2009536956A (ja) 抗癌治療法